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Two stage hepatic resections carry similar risk of adverse outcomes as
single stage resections
The barrier to hepatic resection of insufficient hepatic remnant continues to be pushed back. One
method of increasing the future liver remnant (FLR) is to perform a two stage resection with portal vein
occlusion between the two procedures. In this issue of HPB, Schadde et al. describe a retrospective review
from a prospectively collected database comparing patients undergoing single stage right or extended
right sided resections against a group undergoing a 2-stage resection due to insufficient FLR (<30%).
Endpoints were well defined and the study showed no difference in severity of major complications
between the two groups although many of the secondary endpoints could not be assessed reliably due to
the small sample size and infrequency of the endpoints in question. Data not provided included the
number of patients who did not make it to the second stage due to failure of FLR hypertrophy or disease
progression and it is not clear whether complications of both stages for the 2-stage were included in the
analysis. This may be important as the authors discuss these results against the outcomes from associating
liver partition with portal vein ligation for staged hepatectomy (ALPPS). In future it will be important for
such comparisons to be made on an intention to treat analysis. The other information not imparted is the
timing between the two procedures as there is a temporal difference between volumetric hypertrophy and
“functional hypertrophy” of the FLR. It may be that understanding the interaction between time and
functional hypertrophy is an important determinant of outcome. Currently, the two stage approach
seems to be able to achieve effective short term outcomes for patients with an insufficient FLR.
Saxon Connor
Biopsy of Hepatocellular carcinoma and the sword of Damocles
In the context of liver transplantation there is considerable variation, around the world and even from
centre to centre, in themanagement of HCC.We know from pathological studies that poor differentiation
and microvascular invasion are associated with worse prognosis after liver transplantation. Some centres
have now incorporated this information into their assessment pathway by undertaking routine biopsy of
HCC to obtain information on these pathological factors. In this issue of HPB, Young and colleagues from
Leeds, United Kingdom looked at pre-transplant liver biopsies and compared them with liver explant
pathology. They found considerable discrepancies between findings on pre-operative biopsy and explant
pathology with biopsy often underscoring. In particular the largest lesion was often not representative of
other tumours in the liver. This is important information because it brings into question the validity of
using a tool which may provide false reassurance. In biological terms there is of course no reason why one
HCC should be the same as another, since although they have arisen in the same environment and under
similar stimulants they are not clonal in nature. Multiple biopsies would perhaps address some issues of
sample bias but would incur unacceptable risk of needle-track seeding and other complications such as
bleeding. The role of biopsy is probably best reserved for those cases where there is significant doubt
about whether a lesion is an HCC or not and its role as a determinant of tumour biology may hopefully
be superceded by biomarker discovery or a safer and more reliable assessment.
Stephen J Wigmore
Preparing for a brighter tomorrow
How can we gauge prognosis for today’s victims of pancreatic cancer? What can we measure that tells
patients whether they are responding to difficult therapies or not? If one is a responder, what does that
really mean? If one is a non-responder, what should a patient do? Arshad et al. evaluated patients with
locally advanced or metastatic pancreatic cancer who were treated with gemcitabine followed immedi-
ately by intravenous omega-3 fish oil emulsion. At baseline, and with each weekly treatment, whole blood
was collected and 14 pro-inflammatory circulating cytokines and growth factors (CAF) were measured by
multiplex array. Patients with >30% decrease for a CAF during treatment were considered responders,
and these trends were correlated to overall (OS) and progression-free survival (PFS). High expressors of
IL-6 and IL-8 had significantly shorter median OS than low expressors. PDGF-responders also seemed to
live longer. But these life extensions were only in terms of weeks. Because of this, the value of supplement
fish oil is lost on me.Most major chemotherapy trials in advanced pancreatic cancer show that treatment
provides but a few weeks of added life. It remains a sad but bottom line. And so, what is the value of
deriving indicators of treatment response? Probably nothing as we languish amidst today’s ineffective
therapies. But should that day come when a breakthrough therapy arrives, we should and will need to be
ready to go. That is why this paper is important.
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